In the last eight years, a lot of interesting work has been done on developing salvinorin analogues. Probably the most interesting result of these studies is the development of the compound herkinorin (2-benzoyl salvinorin B). It possesses only weak activity at the kappa-opioid receptor (the primary site of action of salvinorin A), but is a relatively potent and fully efficacious agonist at the mu-opioid receptor (the primary site of action of morphine).
Since it was first reported in 2005, the compound has been the subject of several studies. At some point I'll try to follow up with a concise summary of the data, but for now at least here's a bibliography of papers concerned with this analogue.
Notice that some of these studies are very new, the most recent (Lamb et al. 2011) hasn't even been printed yet, and has only been available online for less than a month... Now that's a paper I'd love to read!
Since it was first reported in 2005, the compound has been the subject of several studies. At some point I'll try to follow up with a concise summary of the data, but for now at least here's a bibliography of papers concerned with this analogue.
Notice that some of these studies are very new, the most recent (Lamb et al. 2011) hasn't even been printed yet, and has only been available online for less than a month... Now that's a paper I'd love to read!
- Butelman, E.R., S. Rus, D.S. Simpson, A. Wolf, T.E. Prisinzano, and M.J. Kreek. 2008. "The effects of herkinorin, the first μ-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates." The Journal of Pharmacology and Experimental Therapeutics 327(1): 154-160. [link]
- Groer, C.E., K. Tidgewell, R.A. Moyer, W.W. Harding, R.B. Rothman, T.E. Prisinzano, and L.M. Bohn. 2007. "An opioid agonist that does not induce μ-opioid receptor–arrestin interactions or receptor internalization." Molecular Pharmacology 71(2): 549-557. [link]
- Harding, W.W., K. Tidgewell, N. Byrd, H. Cobb, C.M. Dersch, E.R. Butelman, R.B. Rothman, and T.E. Prisinzano. 2005. "Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands." Journal of Medicinal Chemistry 48(15): 4765-4771. [link]
- Ji, F., Z. Wang, J. Riley, R. Liu, and W.M. Armstead. "Herkinorin dilates cerebral vessels via kappa opioid receptor and cAMP in a piglet model." Abstract of a presentation given at the American Society of Anesthesiologists Annual Meeting, Chicago, Illinois, 16 Oct 2011. [link]
- Lamb, K., K. Tidgewell, D.S. Simpson, L.M. Bohn, and T.E. Prisinzano. 2011. "Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology." Drug and Alcohol Dependence (article in press). doi:10.1016/j.drugalcdep.2011.10.026. [no link]
- Tidgewell, K.J. 2007. "Development of novel analgesics from the neoclerodane diterpene natural product salvinorin A." PhD thesis, University of Iowa. [see notes in post #37]
- Tidgewell, K., W.W. Harding, A. Lozama, H. Cobb, K. Shah, P. Kannan, C.M. Dersch, D. Parrish, J.R. Deschamps, R.B. Rothman, and T.E. Prisinzano. 2006. "Synthesis of salvinorin A analogues as opioid receptor probes." Journal of Natural Products 69(6): 914-918. [link]
- Tidgewell, K., C.E. Groer, W.W. Harding, A. Lozama, M. Schmidt, A. Marquam, J. Hiemstra, J.S. Partilla, C.M. Dersch, R.B. Rothman, L.M. Bohn, and T.E. Prisinzano. 2008. "Herkinorin analogues with differential β-arrestin-2 interactions." Journal of Medicinal Chemistry 51(8): 2421-2431. [link]
- Xu, H., J.S. Partilla, X. Wang, J.M. Rutherford, K. Tidgewell, T.E. Prisinzano, L.M. Bohn, and R.B. Rothman. 2007. "A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence." Synapse 61(3): 166-175.
- Xu, H., X. Wang, J.S. Partilla, K. Bishop-Mathis, T.S. Benaderet, C.M. Dersch, D.S. Simpson, T.E. Prisinzano, R.B. Rothman. 2008. "Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors." Brain Research Bulletin 77(1): 49-54. [link]